Sarepta’s stock plummets as disappointing trial data raise questions on DMD drug’s success
Up next
Author


Sarepta’s stock sank after studies of Duchenne muscular dystrophy treatments failed their primary endpoints.

You May Also Like
Lululemon shares jump on boosts to stock buyback, profit forecast

Lululemon shares jump on boosts to stock buyback, profit forecast

Shares of Lululemon Athletica jumped after hours Wednesday, after the yoga-wear maker…
Want financial advice from Will Ferrell? Here’s what he told NBA player Austin Reaves.

Want financial advice from Will Ferrell? Here’s what he told NBA player Austin Reaves.

The 26-year-old — who signed a four-year, $54 million contract with the…
Tesla sales have ‘significantly underperformed’ in all key regions, analyst says

Tesla sales have ‘significantly underperformed’ in all key regions, analyst says

Mizuho lowers its price target by 16.5% to reflect all of the…
Stocks see worst wipeout since 2022. Here’s what might happen next.

Stocks see worst wipeout since 2022. Here’s what might happen next.

Investors say the pullback isn’t over yet — but will ultimately present…